At 5.3% CAGR, the Europe Acute Pancreatitis Market is projected to be worth US$ 2,260.69 million by 2030, says Business Market Insights

According to Business Market Insights’ research, the Europe acute pancreatitis market was valued at US$ 1,492.10 million in 2022 and is expected to reach US$ 2,260.69 million by 2030, registering a CAGR of 5.3% from 2022 to 2030. Rise in pancreatic cancer cases due to acute pancreatitis, rising incidence of diabetes following acute pancreatitis, and upsurge in number of R&D activities and awareness programs on acute pancreatitis are among the critical factors attributed to the Europe acute pancreatitis market expansion.             

Extensive research studies are being conducted globally to investigate the etiology, progress, and treatment of acute pancreatitis. The National Pancreas Foundation (NPF) provides multiple research grants worth ~US$ 50,000 per project. To date, the NPF has provided more than US$ 5 million for 133 ground-breaking research projects. A grant is awarded for a period of a year to diagnose and/or treat pancreatitis, pancreatic cancer, or pediatric pancreatitis. Further, several ongoing international efforts are being made to define the epidemiology and pathophysiology of acute pancreatitis. Thus, R&D activities and awareness programs on acute pancreatitis for the development of effective therapies (through direct and indirect means) are expected to be highly fruitful for companies in the Europe acute pancreatitis market.

On the contrary, side effects of pancreatitis and pancreatic cancer treatments hampers on the growth of Europe acute pancreatitis market. 

Based on offerings, the Europe acute pancreatitis market is segmented into medications, diagnosis, and others. The diagnosis segment held 56.3% share of Europe acute pancreatitis market in 2022, amassing US$ 840.53 million. It is projected to garner US$ 1,268.13 million by 2030 to expand at 5.3% CAGR during 2022–2030.

Based on method, the Europe acute pancreatitis market is segmented into gallstones, alcoholism, genetic disorders, infection, and others. The gallstones segment held 47.4% share of Europe acute pancreatitis market in 2022, amassing US$ 707.64 million. It is projected to garner US$ 1,102.55 million by 2030 to expand at 5.7% CAGR during 2022–2030.

Based on end user, the Europe acute pancreatitis market is divided into hospitals, diagnostic laboratories, ambulatory surgical centres, and others. The hospitals segment held 74.8% share of Europe acute pancreatitis market in 2022, amassing US$ 1,115.70 million. It is projected to garner US$ 1,679.68 million by 2030 to expand at 5.2% CAGR during 2022–2030.

Based on country, the Europe acute pancreatitis market has been categorized into the U.K., Germany, France, Italy, Spain, the Nordic Countries, the Netherlands, and the Rest of Europe. Our regional analysis states that Germany captured 29.5% share of Europe acute pancreatitis market in 2022. It was assessed at US$ 439.42 million in 2022 and is likely to hit US$ 645.88 million by 2030, exhibiting a CAGR of 4.9% during 2022–2030.            

Key players operating in the Europe acute pancreatitis market are Abbott Laboratories, Actim Oy, Baxter International Inc, Boston Scientific Corp, Dynavax Technologies Corp, Fresenius Kabi AG, GE HealthCare Technologies Inc, Koninklijke Philips NV, Medtronic Plc, and Samsung Healthcare, among others.

• In Oct 2021; Samsung Medison, a global medical equipment company and an affiliate of Samsung Electronics, introduced the V8, a new high-end ultrasound system that provides enhanced image quality, usability and convenience for all medical professionals.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com